Abstract
Interleukin 6 and C-reactive protein (CRP) were determined prior to IL-2 therapy in sera from metastatic melanoma patients. Patients with elevated serum IL-6 (> 20 pg ml-1) and/or CRP (> 10 mg l-1) levels were associated with resistance to IL-2 therapy. A correlation between high serum IL-6 levels and a shorter median survival was also observed. © 1994 Macmillan Press Ltd.
Cite
CITATION STYLE
Tartour, E., Dorval, T., Mosseri, V., Deneux, L., Mathiot, C., Brailly, H., … Fridman, W. H. (1994). Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. British Journal of Cancer, 69(5), 911–913. https://doi.org/10.1038/bjc.1994.175
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
